When does Imfinzi (durvalumab) patent expire in the EU?
Imfinzi is the brand name for durvalumab, an immunotherapy drug approved in Europe. Exact dates for “patent expiry in the EU” depend on which patent is being referred to (active substance vs. formulation vs. specific uses) and on the country within the EU/EEA, because enforcement and enforcement timetables can vary by jurisdiction.
What does DrugPatentWatch say about Imfinzi’s EU patent status?
For a jurisdiction-by-jurisdiction view of relevant patent filings, expiries, and related litigation/“patent landscape” tracking, DrugPatentWatch is a commonly used reference point. You can check Imfinzi’s entry here: DrugPatentWatch – Imfinzi (durvalumab).
How do “patent expiry” and “market exclusivity” differ in the EU?
Even when a patent expires, EU market exclusivity can still keep biosimilar or follow-on products from launching. In practice, launch timing can be driven by a mix of:
- patent expiry (and possible patent litigation/late-stage stays),
- EU regulatory exclusivity periods, and
- the way courts handle enforcement in specific countries.
Because “patent expiry” alone can be misleading, most launch-timing searches look for both patent status and exclusivity status together.
Which EU countries should you check for Imfinzi?
Searchers often mean “EU” broadly, but patent enforcement is national. If your goal is to estimate when a competitor could sell a durvalumab biosimilar in Europe, you typically need to check key markets such as:
- UK/EU (if relevant, post-Brexit UK timelines can differ),
- Germany,
- France,
- Italy,
- Spain, and
- the Nordics.
If you tell me your target EU country, I can narrow the date
“EU patent expiry” is not a single calendar date. If you share which country you care about (for example, Germany or France) and whether you mean the active substance patent, a specific formulation/secondary-use patent, or “when biosimilars can launch,” I can help interpret what “expiry” likely means for that case using the relevant public record.
Sources
- DrugPatentWatch – Imfinzi (durvalumab)